Scaffold Hopping from Quinazoline to Tetrahydropyrido[3,4- d ]pyrimidine: Enhancing the Potency and Selectivity of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
In this work, a series of tetrahydropyrido[3,4-d]pyrimidine derivatives were rationally designed as HIV-1 non-nucleoside reverse transcriptase inhibitors via scaffold modification. Most compounds demonstrated promising potency against wild-type HIV-1 (IIIB) and clinically relevant mutants. Notably, 10p showed the strongest activity against HIV-1 IIIB, L100I, K103N, Y188C, Y188L, and E138K (EC50 = 2.4−16.5 nM). Importantly, 10p maintained potent efficacy against F227L/V106A (EC50 = 12.3 nM) and K103N/Y181C (EC50 = 21.7 nM). In vitro assessment revealed that the metabolic clearance rate of 10p in human liver microsomes was moderately lower than that of rilpivirine. Additionally, 10p showed a low potential for CYP-mediated drug interactions and had a negligible inhibitory effect on the hERG potassium channel. In the acute oral toxicity study in mice, no adverse effects were observed at a dose of up to 2000 mg/kg. These findings identify 10p as a promising lead compound for further development.
Authors
- Limin Zhao (ORCID: https://orcid.org/0000-0002-1004-9508)
- Phuong‐Thao Tran (ORCID: https://orcid.org/0000-0003-4855-2544)
- Christophe C. Pannecouque (ORCID: https://orcid.org/0000-0002-1254-4473)
- Fen‐Er Chen (ORCID: https://orcid.org/0000-0002-6734-3388)
- Erik De Clercq (ORCID: https://orcid.org/0000-0002-2985-8890)
- Li Qiang Wan (ORCID: https://orcid.org/0000-0002-9362-9806)
- Shuai Wang (ORCID: https://orcid.org/0000-0003-0718-1820)
- Yujie Zhang (ORCID: https://orcid.org/0000-0001-7238-1525)
- Xiaomei Chen (ORCID: https://orcid.org/0000-0001-9790-4513)
- Peng Qi
- Lingbo Qu
- Ling Dong
- Zhen-Zhu Lei
- Yu-Ting Niu
- Hao Deng
- Qian Xu
- Xian-Kai Li
- Peng Liu
Institutions
- Fudan University (CN)
- Zhengzhou University (CN)
- Henan Academy of Sciences (CN)
- Hanoi University of Pharmacy (VN)
- Jiangxi Normal University (CN)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c02971
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Fudan University
- National Key Research and Development Program of China